Emergent Biosolutions Inc. $EBS Shares Sold by Truist Financial Corp

Truist Financial Corp trimmed its position in Emergent Biosolutions Inc. (NYSE:EBS) by 25.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 219,452 shares of the biopharmaceutical company’s stock after selling 74,342 shares during the period. Truist Financial Corp owned 0.42% of Emergent Biosolutions worth $2,712,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in EBS. Legal & General Group Plc acquired a new position in shares of Emergent Biosolutions in the 2nd quarter valued at $31,000. Torren Management LLC acquired a new position in shares of Emergent Biosolutions in the 4th quarter valued at $37,000. Raymond James Financial Inc. acquired a new position in shares of Emergent Biosolutions in the 2nd quarter valued at $53,000. Farther Finance Advisors LLC increased its position in shares of Emergent Biosolutions by 361.3% in the 4th quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 4,827 shares during the period. Finally, BNP Paribas Financial Markets increased its position in shares of Emergent Biosolutions by 133.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 10,942 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 6,246 shares during the period. 78.40% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

EBS has been the topic of several recent research reports. Weiss Ratings lowered shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday. HC Wainwright lowered their price target on shares of Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating on the stock in a report on Monday, March 9th. Finally, Wall Street Zen lowered shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $12.00.

Emergent Biosolutions Trading Down 5.0%

EBS stock opened at $8.51 on Wednesday. The company’s 50-day simple moving average is $8.36 and its 200-day simple moving average is $10.29. The company has a quick ratio of 2.08, a current ratio of 4.29 and a debt-to-equity ratio of 1.10. Emergent Biosolutions Inc. has a 52-week low of $5.30 and a 52-week high of $14.06. The firm has a market cap of $439.23 million, a P/E ratio of -30.38 and a beta of 2.33.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.46. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%. The firm had revenue of $156.10 million during the quarter, compared to the consensus estimate of $145.00 million.

Insider Activity at Emergent Biosolutions

In related news, Director Kathryn C. Zoon sold 17,202 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $8.40, for a total transaction of $144,496.80. Following the completion of the transaction, the director owned 79,941 shares in the company, valued at $671,504.40. This represents a 17.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sujata Tyagi Dayal sold 13,761 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $8.40, for a total transaction of $115,592.40. Following the completion of the sale, the director owned 100,563 shares of the company’s stock, valued at approximately $844,729.20. The trade was a 12.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 61,925 shares of company stock worth $518,312 in the last quarter. Company insiders own 6.00% of the company’s stock.

Emergent Biosolutions Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.